Prestige Wealth Management Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.14K | Sell |
25
-19
| -43% | -$2.39K | ﹤0.01% | 649 |
|
|
2025
Q1 | $4.87K | Hold |
44
| – | – | ﹤0.01% | 564 |
|
|
2024
Q4 | $6.01K | Buy |
44
+19
| +76% | +$2.59K | ﹤0.01% | 559 |
|
|
2024
Q3 | $2.88K | Buy |
25
+2
| +9% | +$230 | ﹤0.01% | 701 |
|
|
2024
Q2 | $3.17K | Buy |
23
+3
| +15% | +$413 | ﹤0.01% | 630 |
|
|
2024
Q1 | $2.76K | Sell |
20
-18
| -47% | -$2.48K | ﹤0.01% | 689 |
|
|
2023
Q4 | $5.01K | Buy |
38
+21
| +124% | +$2.77K | ﹤0.01% | 581 |
|
|
2023
Q3 | $1.91K | Buy |
17
+13
| +325% | +$1.46K | ﹤0.01% | 742 |
|
|
2023
Q2 | $378 | Sell |
4
-18
| -82% | -$1.7K | ﹤0.01% | 1011 |
|
|
2023
Q1 | $2.23K | Sell |
22
-44
| -67% | -$4.45K | ﹤0.01% | 726 |
|
|
2022
Q4 | $7.88K | Buy |
66
+27
| +69% | +$3.23K | ﹤0.01% | 508 |
|
|
2022
Q3 | $4K | Buy |
39
+6
| +18% | +$615 | ﹤0.01% | 603 |
|
|
2022
Q2 | $3K | Hold |
33
| – | – | ﹤0.01% | 697 |
|
|
2022
Q1 | $3K | Buy |
+33
| New | +$3K | ﹤0.01% | 722 |
|
|
2021
Q2 | – | Sell |
-67
| Closed | -$6K | – | 1007 |
|
|
2021
Q1 | $6K | Buy |
67
+23
| +52% | +$2.06K | ﹤0.01% | 584 |
|
|
2020
Q4 | $4K | Buy |
+44
| New | +$4K | ﹤0.01% | 637 |
|